Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA

Phase 2 Recruiting 60 enrolled Elgan Pharma Ltd.

RandomizedParallel-groupQuadruple-blindOther

Summary

To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.

Timeline

Start: 2025-10-28
Primary completion: 2027-06
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	ELGN-2112	Protein / enzyme biologic	—	—

Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA

Summary

Timeline

Drugs

Indications